Recent submissions
Now showing items 1421-1440 of 4701
-
Assessment of delivered rectal dose in prostate cancer radiotherapy
(Institute of Cancer Research (University Of London), 2021-11-30)Prostate radiotherapy gives excellent long-term disease control; however, morbidity from treatment can negatively impact quality of life. To minimise the risk of toxicity a treatment plan is created, which meets dose volume ... -
Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
Purpose The VIT-0910 trial was conducted to evaluate efficacy and safety of the vincristine-irinotecan combination with and without temozolomide (VIT and VI, respectively) in relapsed or refractory rhabdomyosarcoma (RMS). ... -
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.
(AMER ASSOC CANCER RESEARCH, 2021-10-15)PURPOSE: To investigate the activity of niraparib in patients with germline-mutated BRCA1/2 (gBRCAm) advanced breast cancer. PATIENTS AND METHODS: BRAVO was a randomized, open-label phase III trial. Eligible patients had ... -
Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project.
(BMC, 2021-10-26)BACKGROUND: Adaptive designs offer great promise in improving the efficiency and patient-benefit of clinical trials. An important barrier to further increased use is a lack of understanding about which additional resources ... -
Recent advances in testicular germ cell tumours.
(Faculty Opinions Ltd, 2021-01-01)Testicular germ cell tumours (TGCTs) are the most common solid tumours in young men and have an excellent overall cure rate and prognosis. In most patients, localised disease is cured by surgery alone, and a minority of ... -
A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer.
(ELSEVIER IRELAND LTD, 2021-08-19)Bladder preservation with trimodality treatment (TMT) is an alternative strategy to radical cystectomy (RC) for the management of localised muscle invasive bladder cancer (MIBC). TMT comprises of transurethral resection ... -
Accelerating Whole-Body Diffusion-weighted MRI with Deep Learning-based Denoising Image Filters.
(RADIOLOGICAL SOC NORTH AMERICA (RSNA), 2021-09-01)PURPOSE: To use deep learning to improve the image quality of subsampled images (number of acquisitions = 1 [NOA1]) to reduce whole-body diffusion-weighted MRI (WBDWI) acquisition times. MATERIALS AND METHODS: Both ... -
Relationship between genetically determined telomere length and glioma risk.
(OXFORD UNIV PRESS INC, 2022-02-01)BACKGROUND: Telomere maintenance is increasingly recognized as being fundamental to glioma oncogenesis with longer leukocyte telomere length (LTL) reported to increase risk of glioma. To gain further insight into the ... -
Developing biomarker guided treatments for colorectal cancer
(Institute of Cancer Research (University Of London), 2021-09-30) -
Reference dosimetry of MRI-guided radiotherapy machines
(Institute of Cancer Research (University Of London), 2021-09-30)A cutting-edge cancer treatment modality, that integrates MRI guidance and delivery of radiotherapy (MRIgRT), sets a new standard for personalised radiotherapy. There are, however, aspects around the accurate determination ... -
Hypofractionation: less is more?
(Impact Journals, LLC, 2021-08-17)One third of patients with bladder cancer present with muscle invasive bladder cancer (MIBC) which has a poor prognosis. International guidelines for the management of MIBC recommend radical cystectomy or bladder-preserving ... -
A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours.
(SPRINGERNATURE, 2021-01-19)BACKGROUND: This is a first-in-human study with TAS-119, an Aurora A kinase (AurA) inhibitor. METHODS: Patients with advanced, refractory, solid tumours were enrolled into 5 dose escalation cohorts (70-300 mg BID, 4 days ... -
Optimising head and neck radiotherapy treatment using adaptive radiotherapy
(Institute of Cancer Research (University Of London), 2021-10-31)Radiotherapy delivery in head and neck cancer (HNC) has dramatically improved recently with the introduction of advanced techniques such as intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy ... -
Functional studies of genome architectural proteins CTCF and ZNF143
(Institute of Cancer Research (University Of London), 2021-09-30)The genome architecture and gene transcription are interdependent. The way chromatin is packed within the nucleus controls when and how genes are expressed. A lot of chromatin interacting proteins are involved to ensure ... -
Revealing mechanisms of metabolic pathways associated with cancer pain
(Institute of Cancer Research (University Of London), 2021-06-30)Dysregulation of lipid metabolism is a hallmark of oncogenesis. Many lipid metabolites have been implicated in non-cancer pain states, but their role in cancer-related pain has yet to be firmly established. Previous work ... -
Defining the role of SF3B1K700E mutations in ER+ breast cancer
(Institute of Cancer Research (University Of London), 2021-09-30)Mutations in SF3B1, a component of the RNA splicing machinery, underpin a number of aggressive cancers. Hotspot mutations in SF3B1 are present in around 3% of breast cancers, are enriched in oestrogen receptor positive ... -
Tracking the molecular and metabolic fingerprints of inhalational versus intravenous anaesthetics in preclinical models of breast cancer
(Institute of Cancer Research (University Of London), 2021-09-30) -
Improving outcomes in older women with ovarian cancer
(Institute of Cancer Research (University Of London), 2021-09-30)Background: Older women have disproportionately poorer survival outcomes for ovarian cancer. Sarcopenia, the loss of muscle mass and density is of interest as a potential non-invasive biomarker of frailty. Little is ... -
Triplet combination of palbociclib, taselisib and fulvestrant and biomarkers for CDK4/6 and PI3-kinase inhibition in breast cancer
(Institute of Cancer Research (University Of London), 2021-09-30)Targeting the commonly upregulated cell-cycle and PI3-kinase pathway in breast cancer are two of the most novel approaches to tackle the disease, with both strategies having led to clinically meaningful results and licensed ...